Recommendations for the use of genetic testing in the clinical evaluation of inherited cardiac arrhythmias associated with sudden cardiac death: Canadian cardiovascular society/Canadian heart rhythm society joint position paper

Canadian Journal of Cardiology

Volumn 27, Issue 2, 2011, Pages 232-245

  Gollob, Michael H ^a   Blier, Louis ^b   Brugada, Ramon ^c   Champagne, Jean ^b   Chauhan, Vijay ^d   Connors, Sean ^e   Gardner, Martin ^f   Green, Martin S ^a   Gow, Robert ^g   Hamilton, Robert ^h   Harris, Louise ^d   Healey, Jeff S ⁱ   Hodgkinson, Kathleen ^j   Honeywell, Christina ^g   Kantoch, Michael ^k   Kirsh, Joel ^h   Krahn, Andrew ⁿ   Mullen, Michelle ^g   Parkash, Ratika ^f   Redfearn, Damian ^l   Rutberg, Julie ^a   Sanatani, Shubhayan ^m   Woo, Anna ^d   more..

^a UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

^b LAVAL UNIVERSITY   (Canada)

^c MONTREAL HEART INSTITUTE   (Canada)

^d TORONTO GENERAL HOSPITAL   (Canada)

^e MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^f DALHOUSIE UNIVERSITY   (Canada)

^g CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

^h HOSPITAL FOR SICK CHILDREN   (Canada)

ⁱ MCMASTER UNIVERSITY   (Canada)

^j MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^k UNIVERSITY OF ALBERTA HOSPITAL   (Canada)

^l QUEEN S UNIVERSITY   (Canada)

^m UNIVERSITY OF BRITISH COLUMBIA   (Canada)

ⁿ UNIVERSITY OF WESTERN ONTARIO   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FLECAINIDE; QUINIDINE; SPIRONOLACTONE;

ARTICLE; AUTOPSY; BRUGADA SYNDROME; CARDIOVASCULAR RISK; CATECHOLAMINERGIC POLYMORPHIC VENTRICULAR TACHYCARDIA; CLINICAL EVALUATION; CONGESTIVE CARDIOMYOPATHY; COUNSELING; DESMOSOME; DIAGNOSTIC ACCURACY; DISEASE ASSOCIATION; ELECTROCARDIOGRAM; ETHICS; FAMILY; GENE MUTATION; GENETIC SCREENING; HEALTH CARE ORGANIZATION; HEART ARREST; HEART ARRHYTHMIA; HEART RIGHT VENTRICLE DYSPLASIA; HEREDITY; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; LONG QT SYNDROME; MEDICAL DECISION MAKING; MEDICAL SPECIALIST; PRACTICE GUIDELINE; QT PROLONGATION; RESUSCITATION; SUDDEN DEATH; SUDDEN INFANT DEATH SYNDROME; SYNCOPE; CANADA; INCIDENCE; MEDICAL SOCIETY; MORTALITY; REPRODUCIBILITY; REVIEW; STANDARD;

ARRHYTHMIAS, CARDIAC; CANADA; DEATH, SUDDEN, CARDIAC; GENETIC TESTING; HUMANS; INCIDENCE; PRACTICE GUIDELINES AS TOPIC; REPRODUCIBILITY OF RESULTS; SOCIETIES, MEDICAL;

EID: 79957978324     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2010.12.078     Document Type: Article

References (110)

1. Taggart NW, Haglund CM, Tester DJ, Ackerman MJ. Diagnostic miscues in congenital long QT syndrome. Circulation 2007;115:2613-20.
2. Bai R, Napolitano C, Bloise R, Monteforte N, Priori SG. Yield of genetic screening in inherited cardiac channelopathies: how to prioritize access to genetic testing. Circ Arrhythm Electrophysiol 2009;2:6-15.
3. Ackerman MJ. The longQTsyndrome: ion channel diseases of the heart. Mayo Clin Proc 1998;73:250-69.
4. Vincent GM. The molecular genetics of the long QT syndrome: genes causing fainting and sudden death. Annu Rev Med 1998;49:263-74.
5. Priori SG, Schwartz PJ, Napolitano C, et al. Risk stratification in the long-QT syndrome. N Engl J Med 2003;348:1866-74.
6. Shimizu W, Horie M, Ohno S, et al. Mutation site-specific differences in arrhythmic risk and sensitivity to sympathetic stimulation in the LQT1 form of congenital long QT syndrome: multicenter study in Japan. J Am Coll Cardiol 2004;44:117-25.
7. Kimbrough J, Moss AJ, Zareba W, et al. Clinical implications for affected parents and siblings of probands with long-QT syndrome. Circulation 2001;104:557-62.
8. Locati EH, Zareba W, Moss AJ, et al. Age- and sex-related differences in clinical manifestations in patients with congenital long-QT syndrome: findings from the International LQTS Registry. Circulation 1998;97: 2237-44.
9. Moss AJ, Schwartz PJ, Crampton RS, et al. The long QT syndrome: prospective longitudinal study of 328 families. Circulation 1991;84: 1136-44.
10. Schwartz PJ, Moss AM, Vincent GM, et al. Diagnostic criteria for the long QT syndrome. Circulation 1993;88:782-4.
11. Swan H, Saarinen K, Kontula K, et al. Evaluation of QT interval duration and dispersion and proposed clinical criteria in diagnosis of longQT syndrome in patients with a genetically uniform type of LQT1. J Am Coll Cardiol 1998;32:486-91.
12. Neyroud N, Maison-Blanche P, Denjoy I, et al. Diagnostic performance of QT interval variables from 24-h electrocardiography in the long QT syndrome. Eur Heart J 1998;19:158-65.
13. Stramba-Badiale M, Locati EH, Martinelli A, et al. Gender and the relationship between ventricular repolarization and cardiac cycle length during 24-h Holter recordings. Eur Heart J 1997;18:1000-6.
14. Krahn AD, Klein GJ, Yee R. Hysteresis of the RT interval with exercise: a new marker for the long-QT syndrome? Circulation 1997;96:1551-6.
15. Lehmann MH, Suzuki F, Fromm BS, et al. T wave "humps" as a potential electrocardiographic marker of the long QT syndrome. J Am Coll Cardiol 1994;24:746-54.
16. Khositseth A, Hejlik J, Shen WK, et al. Epinephrine-induced T-wave notching in congenital long QT syndrome. Heart Rhythm 2005;2: 141-6.
17. Shimizu W, Noda T, Takaki H, et al. Diagnostic value of epinephrine test for genotyping LQT1, LQT2, and LQT3 forms of congenital long QT syndrome. Heart Rhythm 2004;1:276-83.
18. Heidbuchel H, Corrado D, Biffi A, et al. Recommendations for participation in leisure-time physical activity and competitive sports of patients with arrhythmias and potentially arrhythmogenic conditions. Part II: ventricular arrhythmias, channelopathies and implantable defibrillators. Eur J Cardiovasc Prev Rehabil 2006;13:676-86.
19. Maron BJ, Chaitman BR, Ackerman MJ, et al. Recommendations for physical activity and recreational sports participation for young patients with genetic cardiovascular diseases. Circulation 2004;109: 2807-16.
20. Napolitano C, Priori SG, Schwartz PJ, et al. Genetic testing in the long QT syndrome: development and validation of an efficient approach to genotyping in clinical practice. JAMA 2005;294:2975-80.
21. Tester DJ, Will ML, Haglund CM, et al. Compendium of cardiac channel mutations in 541 consecutive unrelated patients referred for longQT syndrome genetic testing. Heart Rhythm 2005;2:507-17.
22. Splawski I, Shen J, Timothy KW, et al. Spectrum of mutations in long-QT syndrome genes: KVLQT1, HERG, SCN5A, KCNE1, and KCNE2. Circulation 2000;102:1178-85.
23. Brugada J, Brugada R, Brugada P. Right bundle-branch block and STsegment elevation in leads V1 through V3: a marker for sudden death in patients without demonstrable structural heart disease. Circulation 1998;97:457-60.
24. Viskin S, Fish R, Eldar M, et al. Prevalence of the Brugada sign in idiopathic ventricular fibrillation and healthy controls [see comments]. Heart 2000;84:31-6.
25. Veltmann C, Schimpf R, Echternach C, et al. A prospective study on spontaneous fluctuations between diagnostic and non-diagnostic ECGs in Brugada syndrome: implications for correct phenotyping and risk stratification. Eur Heart J 2006;27:2544-52.
26. Matsuo K, Akahoshi M, Nakashima E, et al. Clinical characteristics of subjects with the Brugada-type electrocardiogram. J Cardiovasc Electrophysiol 2004;15:653-7.
27. Furuhashi M, Uno K, Tsuchihashi K, et al. Prevalence of asymptomatic ST segment elevation in right precordial leads with right bundle branch block (Brugada-type ST shift) among the general Japanese population. Heart 2001;86:161-6.
28. Antzelevitch C, Brugada P, Borggrefe M, et al. Brugada syndrome: report of the second consensus conference. Heart Rhythm 2005;2:429-40.
29. Grant AO, Carboni MP, Neplioueva V, et al. Long QT syndrome, Brugada syndrome, and conduction system disease are linked to a single sodium channel mutation. J Clin Invest 2002;110:1201-9.
30. Sarkozy A, Boussy T, Kourgiannides G, et al. Long-term follow-up of primary prophylactic implantable cardioverter-defibrillator therapy in Brugada syndrome. Eur Heart J 2007;28:334-44.
31. Belhassen B, Glick A, Viskin S. Efficacy of quinidine in high-risk patients with Brugada syndrome. Circulation 2004;110:1731-7.
32. Probst V, Veltmann C, Eckardt L, et al. Long-term prognosis of patients diagnosed with Brugada syndrome: results from the FINGER Brugada Syndrome Registry. Circulation 2010; 121:635-43.
33. Priori SG, Napolitano C. Should patients with an asymptomatic Brugada electrocardiogram undergo pharmacological and electrophysiological testing? Circulation 2005;112:279-92; discussion 279-92.
34. Brugada P, Brugada R, Brugada J. Should patients with an asymptomatic Brugada electrocardiogram undergo pharmacological and electrophysiological testing? Circulation 2005;112:279-292; discussion 279-292.
35. Gehi AK, Duong TD, Metz LD, et al. Risk stratification of individuals with the Brugada electrocardiogram: a meta-analysis. J Cardiovasc Electrophysiol 2006;17:577-83.
36. Brugada J, Brugada R, Brugada P. Determinants of sudden cardiac death in individuals with the electrocardiographic pattern of Brugada syndrome and no previous cardiac arrest. Circulation 2003;108:3092-6.
37. Priori SG, Napolitano C, Gasparini M, et al. Clinical and genetic heterogeneity of right bundle branch block and ST-segment elevation syndrome: a prospective evaluation of 52 families. Circulation 2000;102: 2509-15.
38. Priori SG, Napolitano C, Gasparini M, et al. Natural history of Brugada syndrome: insights for risk stratification and management. Circulation 2002;105:1342-7.
39. Schulze-Bahr E, Eckardt L, Breithardt G, et al. Sodium channel gene (SCN5A) mutations in 44 index patients with Brugada syndrome: different incidences in familial and sporadic disease. Hum Mutat 2003; 21:651-2.
40. Roberts JD, Gollob MH. The genetic and clinical features of cardiac channelopathies. Future Cardiol 2010;6:491-506.
41. Antzelevitch C, Pollevick GD, Cordeiro JM, et al. Loss-of-function mutations in the cardiac calcium channel underlie a new clinical entity characterized by ST-segment elevation, short QT intervals, and sudden cardiac death. Circulation 2007;115:442-9.
42. London B, Michalec M, Mehdi H, et al. Mutation in glycerol-3-phosphate dehydrogenase 1 like gene (GPD1-L) decreases cardiac Na+ current and causes inherited arrhythmias. Circulation 2007;116:2260-8.
43. Basso C, Corrado D, Marcus FI, Nava A, Thiene G. Arrhythmogenic right ventricular cardiomyopathy. Lancet 2009;373:1289-300.
44. Muthappan P, Calkins H. Arrhythmogenic right ventricular dysplasia. 2008;51:31-43.
45. McKenna WJ, Thiene G, Nava A, et al. Diagnosis of arrhythmogenic right ventricular dysplasia/cardiomyopathy. Task Force of the Working Group Myocardial and Pericardial Disease of the European Society of Cardiology and of the Scientific Council on Cardiomyopathies of the International Federation of Cardiology. Br Heart J 1994;71:215-18.
46. Marcus FI, McKenna WJ, Sherrill D, et al. Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the task force criteria. Circulation 2010; 121:1533-41.
47. Vasaiwala SC, Finn C, Delpriore J, et al. Prospective study of cardiac sarcoid mimicking arrhythmogenic right ventricular dysplasia. J Cardiovasc Electrophysiol 2009;20:473-6.
48. Roberts JD, Veinot JP, Rutberg J, Gollob MH. Inherited cardiomyopathies mimicking arrhythmogenic right ventricular cardiomyopathy. Cardiovasc Pathol 2010;19:316-20.
49. Sen-Chowdhry S, Syrris P, McKenna WJ. Role of genetic analysis in the management of patients with arrhythmogenic right ventricular dysplasia/ cardiomyopathy. J Am Coll Cardiol 2007;50:1813-21.
50. McKoy G, Protonotarios N, Crosby A, et al. Identification of a deletion in plakoglobin in arrhythmogenic right ventricular cardiomyopathy with palmo-plantar keratoderma and wooly hair (Naxos disease). Lancet 2000;355:2119-24.
51. Rampazzo A, Nava A, Malacirda S, et al. Mutation in human desmoplakin domain binding to plakoglobin causes a dominant form of arrhythmogenic right ventricular cardiomyopathy. Am J Hum Genet 2002;71:1200-6.
52. Gerull B, Heuser A, Wichter T, et al. Mutations in the desmosomal protein plakophilin-2 are common in arrhythmogenic right ventricular cardiomyopathy. Nat Genet 2004;36:1162-4.
53. Pilichou K, Nava A, Basso C, et al. Mutations in desmoglein-2 gene are associated with arrhythmogenic right ventricular cardiomyopathy. Circulation 2006;113:1171-9.
54. Heuser A, Plovie ER, Elinor PT, et al. Mutant desmocollin-2 causes arrhythmogenic right ventricular cardiomyopathy. Am J Hum Genet 2006;71:1081-8.
55. Merner ND, Hodgkinson KA, Haywood AFM, et al. Arrhythmogenic right ventricular cardiomyopathy type 5 is a fully penetrant, lethal arrhythmic disorder caused by a missense mutation in the TMEM43 gene. Am J Human Genet 2008;82:1-13.
56. Syrris P, Ward D, Asimaki A, et al. Clinical expression of plakophilin-2 mutations in familial arrhythmogenic right ventricular cardiomyopathy. Circulation 2006;113:356-64.
57. Dalal D, Molin LH, Piccini J, et al. Clinical features of arrhythmogenic right ventricular dysplasia/cardiomyopathy associated with mutations in plakophilin-2. Circulation 2006;113:1641-9.
58. Yang Z, Bowles NE, Scherer SE, et al. Desmosomal dysfunction due to mutations in desmoplakin causes arrhythmogenic right ventricular dysplasia/ cardiomyopathy. Circ Res 2006;99:646-55.
59. Norgett EE, Hatsell SJ, Carvajal-Huerta L, et al. Recessive mutation in desmoplakin disrupts desmoplakin-intermediate filament interactions and causes dilated cardiomyopathy, wooly hair and keratoderma. Hum Mol Genet 2000;9:2761-6.
60. Syrris P, Ward D, Evans A, et al. Arrhythmogenic right ventricular dysplasia/cardiomyopathy associated with mutations in the desmosomal gene desmocollin-2. Am J Hum Genet 2006;79:978-84.
61. Priori S, Napolitano C, Memmi M, et al. Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia. Circulation 2002;106:69-74.
62. Leenhardt A, Lucet V, Denjoy I, Grau F, Ngoc DD, Coumel P. Catecholaminergic polymorphic ventricular tachycardia in children: a 7-year follow-up of 21 patients. Circulation 1995;91:1512-9.
63. Krahn AD, Gollob M, Yee R, et al. Diagnosis of unexplained cardiac arrest: role of adrenaline and procainamide infusion. Circulation 2005; 112:2228-34.
64. Watanabe H, Chopra N, Laver D, et al. Flecainide prevents catecholamineregic polymorphic ventricular tachycardia in mice and humans. Nat Med 2009;15:380-3.
65. Makanjee B, Gollob MH, Klein GJ, Krahn AD. Ten-year follow-up of cardiac sympathectomy in a young woman with catecholaminergic polymorphic ventricular tachycardia and an implantable cardioverter defibrillator. J Cardiovasc Electrophysiol 2009;20:1167-9.
66. Priori SG, Napolitano C, Tiso N, et al. Mutations in the cardiac ryanodine receptor gene (hRyR2) underlie catecholaminergic polymorphic ventricular tachycardia. Circulation 2001;103:196-200.
67. Lahat H, Pras E, Olender T,et al. A missense mutation in a highly conserved region of CASQ2 is associated with autosomal recessive catecholamine-induced polymorphic ventricular tachycardia in Bedouin families from Israel. Am J Hum Genet 2001;69:1378-84.
68. Tester D, Arya P, Will M, et al. Genotypic heterogeneity and phenotypic mimicry among unrelated patients referred for catecholaminergic polymorphic ventricular tachycardia genetic testing. Heart Rhythm 2006;3: 800-5.
69. Maron BJ, McKenna WJ, Danielson GK, et al. Task Force on Clinical Expert Consensus Documents. American College of Cardiology; Committee for Practice Guidelines. European Society of Cardiology. American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. J Am Coll Cardiol 2003;42: 1687-1713.
70. Wigle ED. Diagnosis of hypertrophic cardiomyopathy. Heart 2001;86: 709-14.
71. Ryan MP, Cleland JGF, French JA, et al. The standard electrocardiogram as a screening test for hypertrophic cardiomyopathy. Am J Cardiol 1995;76:689-94.
72. Maron BJ, Pelliccia A, Spirito P. Cardiac disease in young trained athletes: insights into methods for distinguishing athlete's heart from structural heart disease, with particular emphasis on hypertrophic cardiomyopathy. Circulation 1995;91:1596-1601.
73. Gollob MH, Green MS, Tang A, Roberts R. The PRKAG2 cardiac syndrome: familial ventricular preexcitation, conduction system disease, and cardiac hypertrophy. Curr Opin Cardiol 2002;17: 229-34.
74. Guertl B, Noehammer C, Hoefler G. Metabolic cardiomyopathies. Int J Exp Pathol 2000;81:349-72.
75. McKenna WJ, Behr ER. Hypertrophic cardiomyopathy: management, risk stratification, and prevention of sudden death. Heart 2002;87:169-76.
76. Bos JM, Towbin JA, Ackerman MJ. Diagnostic, prognostic, and therapeutic implications of genetic testing for hypertrophic cardiomyopathy. J Am Coll Cardiol 2009;54:201-11.
77. Richard P, Charron P, Carrier L, et al; EUROGENE Heart Failure Project. Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy. Circulation 2003;107:2227-32.
78. Sachdev B, Takenaka T, Teraguchi H, et al. Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy. Circulation 2002;105:1407-11.
79. Schiffman R, Kopp JB, Austin JB III, et al. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. J Am Med Assoc 2001; 285:2743-59.
80. Pastores GM, Thadhani R. Enzyme-replacement therapy for Anderson-Fabry disease. Lancet 2001;358:601-3.
81. Yang Z, McMahon CJ, Smith LR, et al. Danon disease as an underrecognized cause of hypertrophic cardiomyopathy in children. Circulation 2005;112:1612-7.
82. Gollob MH, Green MS, Tang A S-L, et al. Identification of a gene responsible for Familial Wolff-Parkinson-White Syndrome. New Engl J Med 2001;344:1823-31.
83. Codd MB, Sugrue DD, Gersh BJ, Melton LJ III. Epidemiology of idiopathic dilated and hypertrophic cardiomyopathy: a population-based study in Olmsted County, Minnesota, 1975-1984. Circulation 1989;80: 564-72.
84. Grünig E, Tasman JA, Kücherer H, Franz W, Kübler W, Katus HA. Frequency and phenotypes of familial dilated cardiomyopathy. J Am Coll Cardiol 1998;31:186-94.
85. Hershberger RE, Lindenfeld J, Mestroni L, Seidman CE, Taylor MR, Towbin JA; Heart Failure Society of America. Genetic evaluation of cardiomyopathy: a Heart Failure Society of America practice guideline. J Card Fail 2009;15:83-97.
86. Moss AJ, Hall WJ, Cannom DS, et al; MADIT-CRT Trial Investigators. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med 2009;361:1329-38.
87. Judge DP. Use of genetics in the clinical evaluation of cardiomyopathy. JAMA 2009;302:2471-6.
88. Burkett EL, Hershberger RE. Clinical and genetic issues in familial dilated cardiomyopathy. J Am Coll Cardiol 2005;45:969-81.
89. Hershberger RE, Parks SB, Kushner JD, et al. Coding sequence mutations identified in MYH7, TNNT2, SCN5A, CSRP3, LBD3, and TCAP from 313 patients with familial or idiopathic dilated cardiomyopathy. Clin Transl Sci 2008;1:21-6.
90. Survivors of out-of-hospital cardiac arrest with apparently normal heart: need for definition and standardized clinical evaluation: consensus statement of the Joint Steering Committees of the Unexplained Cardiac Arrest Registry of Europe and of the Idiopathic Ventricular Fibrillation Registry of the United States. Circulation 1997;95:265-72.
91. Wever EF, Robles de Medina EO. Sudden death in patients without structural heart disease. J Am Coll Cardiol 2004;43:1137-44.
92. Maron BJ, Shirani J, Poliac LC, Mathenge R, Roberts WC, Mueller FO. Sudden death in young competitive athletes: clinical, demographic, and pathological profiles. JAMA 1996;276:199-204.
93. Eckart RE, Scoville SL, Campbell CL, et al. Sudden death in young adults: a 25-year review of autopsies in military recruits. Ann Intern Med 2004;141:829-34.
94. Bowker TJ, Wood DA, Davies MJ, et al. Sudden, unexpected cardiac or unexplained death in England: a national survey. QJM 2003;96:269-79.
95. Willinger M, James LS, Catz C. Defining the sudden infant death syndrome (SIDS): deliberations of an expert panel convened by the National Institute of Child Health and Human Development. Pediatr Pathol 1991;11:677-84.
96. Cohle SD, Sampson BA. The negative autopsy: sudden cardiac death or other? Cardiovasc Pathol 2001;10:219-22.
97. Priori SG, Napolitano C, Memmi M, et al. Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia. Circulation 2002;106:69-74.
98. Tester DJ, Kopplin LJ, Creighton W, Burke AP, Ackerman MJ. Pathogenesis of unexplained drowning: new insights from a molecular autopsy. Mayo Clin Proc 2005;80:596-600.
99. Moss AJ, Robinson JL, Gessman L, et al. Comparison of clinical and genetic variables of cardiac events associated with loud noise versus swimming among subjects with the long QT syndrome. Am J Cardiol 1999; 84:876-9.
100. Tester DJ, Spoon DB, Valdivia HH, Makielski JC, Ackerman MJ. Targeted mutational analysis of the RyR2-encoded cardiac ryanodine receptor in sudden unexplained death: a molecular autopsy of 49 medical examiner/coroner's cases. Mayo Clin Proc 2004;79:1380-4.
101. Chugh SS, Senashova O, Watts A, et al. Postmortem molecular screening in unexplained sudden death. J Am Coll Cardiol 2004;43: 1625-9.
102. Tester DJ, Ackerman MJ. Postmortem long QT syndrome genetic testing for sudden unexplained death in the young. J Am Coll Cardiol 2007;49:240-6.
103. Krahn AD, Healey JS, Chauhan V, et al. Systematic assessment of patients with unexplained cardiac arrest: Cardiac Arrest Survivors With Preserved Ejection Fraction Registry (CASPER). Circulation 2009;120: 278-85.
104. Behr E, Wood DA, Wright M, et al. Cardiological assessment of firstdegree relatives in sudden arrhythmic death syndrome. Lancet 2003;362: 1457-9.
105. Tan HL, Hofman N, van Langen IM, van der Wal AC, Wilde AA. Sudden unexplained death: heritability and diagnostic yield of cardiological and genetic examination in surviving relatives. Circulation 2005; 112:207-13.
106. Leach CE, Blair PS, Fleming PJ, et al. Epidemiology of SIDS and explained sudden infant deaths. CESDI SUDI Research Group. Pediatrics 1999;104:e43.
107. Bajanowski T, Vege A, Byard RW, et al. Sudden infant death syndrome (SIDS)-standardised investigations and classification: recommendations. Forensic Sci Int 2007;165:129-43.
108. Bennett MJ, Rinaldo P. The metabolic autopsy comes of age. Clin Chem 2001;47:1145-6.
109. Arnestad M, Crotti L, Rognum TO, et al. Prevalence of long-QT syndrome gene variants in sudden infant death syndrome. Circulation 2007; 115:361-7.
110. Tester DJ, Ackerman MJ. Sudden infant death syndrome: how significant are the cardiac channelopathies? Cardiovasc Res 2005;67:388-96.